Xylobiose在2型糖尿病及代谢综合征研究中显示出潜力，能强化肠道屏障、降低血糖血脂、并减轻氧化应激与炎症。其作为一种口服有效的CLDN2抑制剂和HSP27诱导剂，通过调控肠道屏障功能、细胞保护及miR-122a/miR-33a介导的糖脂代谢通路发挥作用。

[1] Rini DM, Nakamichi Y, Morita T, Inoue H, Mizukami Y, Yamamoto Y, Suzuki T. Xylobiose treatment strengthens intestinal barrier function by regulating claudin 2 and heat shock protein 27 expression in human Caco-2 cells. J Sci Food Agric. 2024 Mar 15;104(4):2518-2525. doi: 10.1002/jsfa.13111. Epub 2023 Nov 29. PMID: 37938188.[2]Lim E, Lim JY, Kim E, Kim YS, Shin JH, Seok PR, Jung S, Yoo SH, Kim Y. Xylobiose, an Alternative Sweetener, Ameliorates Diabetes-Related Metabolic Changes by Regulating Hepatic Lipogenesis and miR-122a/33a in db/db Mice. Nutrients. 2016 Dec 5;8(12):791. doi: 10.3390/nu8120791. PMID: 27929393; PMCID: PMC5188446.